Last updated on December 2019

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype


Brief description of study

The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.

Clinical Study Identifier: NCT02658279

Find a site near you

Start Over

Memorial Sloan Kettering Commack

Commack, NY United States
7.02miles
  Connect »